Solentim at the Palace

This week, members of Solentim’s management team enjoyed the privileged experience of visiting Buckingham Palace. The invitation to a private reception at the Palace followed Solentim’s success in winning two Queen’s Awards for Enterprise, announced in April, the first for Innovation and the second for International Trade.

Solentim at the PalaceThe reception was hosted by The Prince of Wales on behalf of Her Majesty The Queen. Prince Charles and The Duke of Kent, who was also in attendance, spent the evening meeting the award winners.

Aaron Figg, Director, commented “The reception stands as further recognition of the importance and prestige of this achievement, and reflects the hard work put in by the team at Solentim. We are immensely proud to have achieved the rare distinction of receiving two awards in the same year”.

The Queen’s Awards for Enterprise are reserved for outstanding achievement by UK businesses in the categories of innovation, international trade, sustainable development and promoting opportunity through social mobility. They are regarded as the UK’s most prestigious business awards, and are given only to companies or individuals exceptional in their field.

Dr Ian Taylor, Sales and Marketing Director commented on visiting the palace “Solentim’s dedicated and skilled team continue to go from strength to strength, innovating constantly to deliver the cutting edge scientific solutions to our global customers in a fast-changing market. Receiving these awards is recognition for the whole team and we are all thrilled to have been chosen.”

The final stage of receiving these awards will take place later in the year at Solentim’s offices in Wimborne. The Lord-Lieutenant of Dorset will present the awards to the Solentim team at a special reception – we will keep you posted with news and photos from this event.

 

About Solentim

Solentim enables its life science industry customers to develop a greater number of more effective pharmaceuticals to help patients live healthier, for longer.  We do this through designing and manufacturing highly innovative instruments that facilitate the process of commercial cell line development.  This phase of biopharmaceutical production is a high value process which is intrinsically expensive and time consuming.  Our solutions significantly shorten the upstream cell line development workflow process and therefore make drug production faster and more cost effective.  Our products; Cell Metric® and VIPS™represent the next generation of single cell printing and provide documented proof of monoclonality for the FDA and other regulatory bodies.  Five of the world’s top ten pharmaceutical companies use Solentim products. Established in 2010 and with global headquarters in Dorset, UK; the organisation employs over 40 people across the UK, Europe, Asia and the USA.